Jackson Hole Capital Partners’s AstraZeneca AZN Stock Holding History

Jackson Hole Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,610	Closed	-$224K	–	280
2023 Q1	$224K	Hold	1,610	–	–	0.06%	198
2022 Q4	$218K	Buy	+1,610	New	+$202K	0.07%	170
2022 Q3	–	Sell	-1,610	Closed	-$213K	–	263
2022 Q2	$213K	Sell	1,610 -65	-4%	-$8.53K	0.07%	165
2022 Q1	$222K	Buy	+1,675	New	+$201K	0.06%	166

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jackson Hole Capital Partners's AZN Position: Q2 2023 in Review

Jackson Hole Capital Partners sold out of AstraZeneca (AZN) in Q2 2023, closing a stake of 1,610 shares — an estimated $224K sold.

Jackson Hole Capital Partners first reported a position in AZN in Q1 2022 and held it in 4 quarters. The position peaked at $224K in Q1 2023. 1,090 funds tracked by Wall St. Rank hold AZN as of Q2 2023.

Jackson Hole Capital Partners reported no remaining AstraZeneca position as of Q2 2023 after selling out during the quarter.
Jackson Hole Capital Partners sold 1,610 AstraZeneca shares in Q2 2023, an estimated $224K.
Jackson Hole Capital Partners first reported a position in AstraZeneca in Q1 2022 and held it in 4 quarters.
Jackson Hole Capital Partners's AstraZeneca position peaked at $224K in Q1 2023.
1,090 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2023.

Based on Jackson Hole Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.